Bio-Nanocapsule-Liposome Conjugates for In Vivo Pinpoint Drug and Gene Delivery

Takeshi Kasuya, Joohee Jung, Rie Kinoshita, Yasumasa Goh, Takashi Matsuzaki, Masumi Iijima, Nobuo Yoshimoto, Katsuyuki Tanizawa, Shun'ichi Kuroda

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

A bio-nanocapsule (BNC) is an ~ 50-nm hepatitis B virus (HBV) subviral particle comprising HBV envelope L proteins and a lipid bilayer, and is synthesized in recombinant Saccharomyces cerevisiae. When BNCs are administered intravenously in a mouse xenograft model, they can accumulate specifically in human liver-derived tissues and enter cells efficiently by the HBV-derived human liver-specific infection machinery, localized at the outer-membrane pre-S region of the L protein. BNC specificity for the human liver can be altered to other tissues by substituting the pre-S region using targeting molecules (e.g., antibodies, lectins, cytokines). BNCs can spontaneously form complexes with liposomes (LPs) by the membrane fusogenic activity of the pre-S region. LPs containing various therapeutic materials (e.g., chemicals, proteins, DNA, RNA) can therefore be covered with BNCs to form an ~ 150-nm BNC-LP conjugate. BNC-LP conjugates injected intravenously can deliver incorporated materials to target tissues specifically and efficiently by utilizing the HBV-derived infection machinery. The stability of BNC-LP conjugates in the blood circulation is similar to that of PEGylated LPs. In this chapter, we describe the preparation and in vivo application of BNC-LP conjugates, and the potential of BNC-LP conjugates as in vivo pinpoint drug delivery systems.

Original languageEnglish
Pages (from-to)147-166
Number of pages20
JournalMethods in Enzymology
Volume464
Issue numberC
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Nanocapsules
Liposomes
Genes
Viruses
Pharmaceutical Preparations
Hepatitis B virus
Liver
Tissue
Machinery
Viral Envelope Proteins
Membranes
Proteins
Lipid bilayers
Blood Circulation
Hemodynamics
Lipid Bilayers
Virus Diseases
Drug Delivery Systems
Lectins
Heterografts

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Bio-Nanocapsule-Liposome Conjugates for In Vivo Pinpoint Drug and Gene Delivery. / Kasuya, Takeshi; Jung, Joohee; Kinoshita, Rie; Goh, Yasumasa; Matsuzaki, Takashi; Iijima, Masumi; Yoshimoto, Nobuo; Tanizawa, Katsuyuki; Kuroda, Shun'ichi.

In: Methods in Enzymology, Vol. 464, No. C, 2009, p. 147-166.

Research output: Contribution to journalArticle

Kasuya, T, Jung, J, Kinoshita, R, Goh, Y, Matsuzaki, T, Iijima, M, Yoshimoto, N, Tanizawa, K & Kuroda, S 2009, 'Bio-Nanocapsule-Liposome Conjugates for In Vivo Pinpoint Drug and Gene Delivery', Methods in Enzymology, vol. 464, no. C, pp. 147-166. https://doi.org/10.1016/S0076-6879(09)64008-8
Kasuya, Takeshi ; Jung, Joohee ; Kinoshita, Rie ; Goh, Yasumasa ; Matsuzaki, Takashi ; Iijima, Masumi ; Yoshimoto, Nobuo ; Tanizawa, Katsuyuki ; Kuroda, Shun'ichi. / Bio-Nanocapsule-Liposome Conjugates for In Vivo Pinpoint Drug and Gene Delivery. In: Methods in Enzymology. 2009 ; Vol. 464, No. C. pp. 147-166.
@article{9e909c982cc9419fa748c5fbd070bea8,
title = "Bio-Nanocapsule-Liposome Conjugates for In Vivo Pinpoint Drug and Gene Delivery",
abstract = "A bio-nanocapsule (BNC) is an ~ 50-nm hepatitis B virus (HBV) subviral particle comprising HBV envelope L proteins and a lipid bilayer, and is synthesized in recombinant Saccharomyces cerevisiae. When BNCs are administered intravenously in a mouse xenograft model, they can accumulate specifically in human liver-derived tissues and enter cells efficiently by the HBV-derived human liver-specific infection machinery, localized at the outer-membrane pre-S region of the L protein. BNC specificity for the human liver can be altered to other tissues by substituting the pre-S region using targeting molecules (e.g., antibodies, lectins, cytokines). BNCs can spontaneously form complexes with liposomes (LPs) by the membrane fusogenic activity of the pre-S region. LPs containing various therapeutic materials (e.g., chemicals, proteins, DNA, RNA) can therefore be covered with BNCs to form an ~ 150-nm BNC-LP conjugate. BNC-LP conjugates injected intravenously can deliver incorporated materials to target tissues specifically and efficiently by utilizing the HBV-derived infection machinery. The stability of BNC-LP conjugates in the blood circulation is similar to that of PEGylated LPs. In this chapter, we describe the preparation and in vivo application of BNC-LP conjugates, and the potential of BNC-LP conjugates as in vivo pinpoint drug delivery systems.",
author = "Takeshi Kasuya and Joohee Jung and Rie Kinoshita and Yasumasa Goh and Takashi Matsuzaki and Masumi Iijima and Nobuo Yoshimoto and Katsuyuki Tanizawa and Shun'ichi Kuroda",
year = "2009",
doi = "10.1016/S0076-6879(09)64008-8",
language = "English",
volume = "464",
pages = "147--166",
journal = "Methods in Enzymology",
issn = "0076-6879",
publisher = "Academic Press Inc.",
number = "C",

}

TY - JOUR

T1 - Bio-Nanocapsule-Liposome Conjugates for In Vivo Pinpoint Drug and Gene Delivery

AU - Kasuya, Takeshi

AU - Jung, Joohee

AU - Kinoshita, Rie

AU - Goh, Yasumasa

AU - Matsuzaki, Takashi

AU - Iijima, Masumi

AU - Yoshimoto, Nobuo

AU - Tanizawa, Katsuyuki

AU - Kuroda, Shun'ichi

PY - 2009

Y1 - 2009

N2 - A bio-nanocapsule (BNC) is an ~ 50-nm hepatitis B virus (HBV) subviral particle comprising HBV envelope L proteins and a lipid bilayer, and is synthesized in recombinant Saccharomyces cerevisiae. When BNCs are administered intravenously in a mouse xenograft model, they can accumulate specifically in human liver-derived tissues and enter cells efficiently by the HBV-derived human liver-specific infection machinery, localized at the outer-membrane pre-S region of the L protein. BNC specificity for the human liver can be altered to other tissues by substituting the pre-S region using targeting molecules (e.g., antibodies, lectins, cytokines). BNCs can spontaneously form complexes with liposomes (LPs) by the membrane fusogenic activity of the pre-S region. LPs containing various therapeutic materials (e.g., chemicals, proteins, DNA, RNA) can therefore be covered with BNCs to form an ~ 150-nm BNC-LP conjugate. BNC-LP conjugates injected intravenously can deliver incorporated materials to target tissues specifically and efficiently by utilizing the HBV-derived infection machinery. The stability of BNC-LP conjugates in the blood circulation is similar to that of PEGylated LPs. In this chapter, we describe the preparation and in vivo application of BNC-LP conjugates, and the potential of BNC-LP conjugates as in vivo pinpoint drug delivery systems.

AB - A bio-nanocapsule (BNC) is an ~ 50-nm hepatitis B virus (HBV) subviral particle comprising HBV envelope L proteins and a lipid bilayer, and is synthesized in recombinant Saccharomyces cerevisiae. When BNCs are administered intravenously in a mouse xenograft model, they can accumulate specifically in human liver-derived tissues and enter cells efficiently by the HBV-derived human liver-specific infection machinery, localized at the outer-membrane pre-S region of the L protein. BNC specificity for the human liver can be altered to other tissues by substituting the pre-S region using targeting molecules (e.g., antibodies, lectins, cytokines). BNCs can spontaneously form complexes with liposomes (LPs) by the membrane fusogenic activity of the pre-S region. LPs containing various therapeutic materials (e.g., chemicals, proteins, DNA, RNA) can therefore be covered with BNCs to form an ~ 150-nm BNC-LP conjugate. BNC-LP conjugates injected intravenously can deliver incorporated materials to target tissues specifically and efficiently by utilizing the HBV-derived infection machinery. The stability of BNC-LP conjugates in the blood circulation is similar to that of PEGylated LPs. In this chapter, we describe the preparation and in vivo application of BNC-LP conjugates, and the potential of BNC-LP conjugates as in vivo pinpoint drug delivery systems.

UR - http://www.scopus.com/inward/record.url?scp=71549162528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71549162528&partnerID=8YFLogxK

U2 - 10.1016/S0076-6879(09)64008-8

DO - 10.1016/S0076-6879(09)64008-8

M3 - Article

VL - 464

SP - 147

EP - 166

JO - Methods in Enzymology

JF - Methods in Enzymology

SN - 0076-6879

IS - C

ER -